NCE Discovery

Home > R&D > Research Protfolio >NCE Discovery


Oncology  Pipelines

For more clinical information, click development stage
(as of May. 2012)
Pipelines Characteristics Development Stage
OraxolTM
 - Paclitaxel +HM30181A
Phase II
licensed out to Kinex (US)
OratecanTM
 - Irinotecan + HM30181A Phase I
licensed out to Kinex (US)
HM781-36B
 - Orally active pan-Her inhibitor Phase I
KX-01
- Src tyrosine kinase and tubulin polymerization inhibitor Phase I
HM61713
 - EGFR mutant selective inhibitor Phase I